Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)


28 Sep 2019


Poster Display session 1


Tumour Site



Daniele Fanale


Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283


D. Fanale1, L. Incorvaia1, G. Badalamenti1, J.L. Iovanna2, D. Olive3, I. De Luca1, M. Silletta4, B. Vincenzi5, V. Bazan1, A. Russo1

Author affiliations

  • 1 Department Of Surgical, Oncological And Oral Sciences, University of Palermo, 90127 - Palermo/IT
  • 2 Inserm U1068, Cnrs Umr 7258, Aix-marseille Université And Institut Paoli-calmettes, Parc Scientifique Et Technologique De Luminy, Marseille, France, Centre de Recherche en Cancérologie de Marseille (CRCM), 13288 - Marseille/FR
  • 3 Team Immunity And Cancer, Inserm U1068, Cnrs Umr 7258, Aix-marseille Université And Institut Paoli-calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), 13288 - Marseille/FR
  • 4 Medical Oncology, Campus Bio-Medico di Roma, 128 - Rome/IT
  • 5 Medical Oncology, Policlinico Universitario Campus Bio-Medico, 00128 - Rome/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3411


Gastrointestinal stromal tumours (GISTs) account for 1% of all primary gastrointestinal cancers. In cancer, suppressive immune checkpoints, including butyrophilin sub-family 3A/CD277 receptors (BTN3A), programmed death protein (PD-1) and its ligand PD-L1, are often hyper-activated to ensure an effective evasion of tumor cells from immune surveillance. Since recent studies showed that PD-1 and PD-L1 expression in cancer may be an important prognostic factor, the aim of our study was to investigate if soluble forms of inhibitory immune checkpoints can help predict survival in metastatic GIST patients.


Using specific homemade ELISA assays not yet commercially available, the plasma PD-1, PD-L1, BTN3A1 and pan-BTN3As levels were analyzed in 20 metastatic GIST patients harbouring c-KIT exon 11 mutations, before starting treatment with 400 mg Imatinib. Survival curves were estimated by using the Kaplan-Meier method and log-rank test to evaluate significant differences among them. Data was generated using the MedCalc software for Windows, version 18.2.1.


Kaplan-Meier survival analysis was used to characterize prognostic relevance of soluble PD-1, PD-L1, BTN3A1 and pan-BTN3As in metastatic GIST patients, suggesting that their plasma levels could serve as survival predictor. For each analyzed biomarker, statistically significant differences in progression free-survival (PFS) between patients with plasma concentrations above and under median values were detected. Plasma level thresholds correlated with shorter survival and poor prognosis were established for PD-1 (>6.89 ng/ml), PD-L1 (>0.74 ng/ml), BTN3A1 (>7.19 ng/ml) and pan-BTN3As (>4.38 ng/ml). Conversely, patients with plasma levels under thresholds showed a median PFS that was approximately 58 months longer than to the previous.


Our study, for the first time, reveals that monitoring the concentration of soluble forms of inhibitory immune checkpoints in plasma can help predict survival in metastatic GIST patients and therefore improve their treatments. We showed that high plasma levels of these immune checkpoints correlate with poor outcome and could be used in future as prognostic factors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.